Publication status: results are available only from the registry record and the company prospectus.
Design: four-period single-dose crossover with one-week washouts; participants who withdrew were not replaced, and 49 participants started the fourth period. The registry states the analysis did not analyze data by period and reported adverse events by treatment group only.
Eligibility differs by source: the registry states AHI 10 to below 20, or 20 or more if other polysomnography criteria were met, while the prospectus states AHI 10 to 45 events/h with randomization limited to participants showing signs of low upper airway collapsibility. Ages were 25 to 65, and exclusions included a history of insomnia and clinically significant cardiac disease.
Open-label extension: 37 of 60 participants received AD109 for 4 weeks without a control group; the reported reductions in hypoxic burden and AHI at week 4 and the SAQLI change versus baseline come from the prospectus.
Withdrawals differ by source: the registry lists first-period non-completion as incorrectly randomized, lost to follow-up, and physician decision (1 each), while the prospectus states two participants withdrew because of adverse events (pleurisy and atrial fibrillation).
Safety: one serious adverse event (possible seizure versus arrhythmia or atrial fibrillation) occurred with AD109 in a participant with a previously undisclosed history of arrhythmia and was considered unrelated to the drug.
Sponsor: the prospectus describes APC-003 as a trial the company initiated.